A spokesperson and attorneys for Smith Drug did not immediately respond to a request for comment. Food and Drug Administration in 2010, was Novo's first-generation blockbuster ‌GLP-1 drug. According to the complaint, Novo unlawfully paid to delay Teva's entry into the generic market as part of a 2019 settlement of patent ‍litigation between the companies.The lawsuit said that generic Victoza would have been on the market in 2023 without ‍Novo and ⁠Teva's agreement. Smith ⁠Drug asked the court for an unspecified amount of monetary damages on behalf of a proposed class of Victoza purchasers.The case is Smith Drug Co v. Novo Nordisk Inc, U.S. District Court for the Eastern District of New York, No. 1:26-cv-00420.For Smith Drug: Garwin Gerstein & Fisher; Faruqi & Faruqi; Berger Montague; Silver Golub & Teitell; Odom & Des Roches; Heim Payne & Chorush; and Smith Segura Raphael & LegerFor Novo: attorney information not yet available (Reporting by Blake Brittain in Washington)>

Source: Economic Times January 25, 2026 13:39 UTC